Jade-Lily C. Jonovski
Elouise K. Bacon
Brandon D. Velie- Equine Genetics and Genomics Group, School of Life and Environmental Science, University of Sydney, Sydney, NSW, Australia
1 Introduction
The capacity to tailor medical treatments to individual genetic profiles is steadily revolutionising modern healthcare. Known as precision medicine, this approach has been used to improve patient outcomes through a variety of medical applications ranging from drug choice to chronic disease management (1–13). Precision medicine seeks to end the “one size fits all” and “trial and error” approaches of medical treatments, minimising adverse effects and improving therapeutic efficacy to ultimately optimise patient outcomes (1–4, 14).
Serving as a cornerstone of precision medicine, pharmacogenetics facilitates the customisation of drug therapy based on an individual's genetic constitution for drug response (1–4, 14–16). For example, in humans, women with a polymorphism in the cytochrome P450 (CYP) gene family, specifically CYP2D6, are advised to pursue alternative treatments for early-stage hormone-receptor positive breast cancer rather than the gold-standard drug tamoxifen. This advice is given based on a loss of function mutation in CYP2D6 resulting in deficient enzyme activity for tamoxifen metabolite catalysis and thus exhibiting poorer clinical outcomes and greater risk of breast cancer recurrence (17, 18). The applicability of these findings exemplifies how pharmacogenetic insights can directly inform clinical decision making and improve therapeutic outcomes; yet in veterinary species, pharmacogenetic approaches remain rare in routine practise.
Although variability in drug response at a species, breed, and individual level is well documented, much of veterinary pharmacogenetics remains in the early stages of research and validation (1, 15, 19). Current veterinary pharmacotherapy relies heavily on standardised dosing regimens based on population averages, disregarding individual variation in pharmacokinetic and pharmacodynamic parameters (13, 15, 16, 19). Breed-specific drug sensitivities, notably in herding breeds such as Collies, have spearheaded the early adoption of pharmacogenetic principles in veterinary practise, with further advances drawn heavily from human and rodent models predominantly in oncology (1, 5–12, 16, 20, 21). Consequently, research has sidelined broader therapeutic areas such as analgesia or chronic disease management.
Despite the overall lag in clinical adoption, several notable examples illustrate that pharmacogenetic principles are not merely theoretical in veterinary medicine. Mutations in genes such as ryanodine receptor 1 (porcine, canine, equine), ATP-binding cassette B-1 (ABCB1; canine), and various CYP (canine, equine) genes have been implicated in the occurrence of adverse effects and variability in drug clearance (1, 10, 22–51). Although clinically relevant, the limited scope identified in current pharmacogenes research highlights the vast opportunity to expand precision medicine principles into fields such as pain management, where failure to individualise therapy can have profound welfare implications.
2 Advancing veterinary pain management
Pain is a fundamental biological mechanism that serves both adaptive and maladaptive roles in animals. Adaptive pain functions as an essential protective response, alerting an individual to potential or actual tissue injury and stimulating behaviours that serve to minimise further harm (52–56). Conversely, maladaptive pain arises when the nociceptive system itself becomes dysfunctional (52–56). Pain manifesting without protective purpose profoundly reduces quality of life and presents significant challenges for veterinary practitioners (52–57). Since adaptive and maladaptive pain often coexist, the aim of veterinary pain management is not to eliminate all nociceptive input but rather to reduce maladaptive pain while preserving protective pain responses (52, 53, 56, 58).
Ensuring effective pain management is integral to improving patient welfare and reducing morbidity (57–61). Traditional approaches to pain management predominantly rely on pharmaceutical interventions. Nonsteroidal anti-inflammatory drugs, opioids, local anaesthetics, and alpha-2 adrenergic receptor agonists remain the foundations of analgesic protocols across species (53, 54, 57, 58). Selection of drugs is purpose-driven, guided by standard industry practise and clinician discretion, while dosage rates are shaped by population-wide efficacy and adjusted for body weight. Such approaches, while pragmatically necessary in the absence of individualised data, implicitly assume uniform pharmacodynamic responses among patients. Clinical observations and emerging pharmacogenetic research stand to increasingly challenge these practises (1–7, 9, 10).
Veterinary clinicians frequently encounter variability in analgesic efficacy, adverse drug reactions, and duration of action even among patients of the same species, breed, and size (21). Nevertheless, the prevailing model for analgesic selection and dosing remains largely reactive rather than predictive, with adjustments typically made only after the emergence of adverse effects or overall treatment failure (53, 54, 57, 58). Such reactive approaches risk prolonged animal suffering and delay effective intervention, undermining trust between owners and veterinary professionals (56–58). Precision medicine offers an opportunity to transform veterinary pain management from a reactive to a proactive discipline. Although gene-mediated analgesic response in animals remains minimally explored, genetic regions have been implicated in the delivery and metabolism of analgesic drugs.
ABCB1 is one of few veterinary pharmacogenes associated with variability in analgesic drug response. P-glycoproteins are integral to drug transport across the blood-brain barrier, with mutations associated with increased central nervous system sensitivity to opioid analgesics in canines (1, 10, 30, 32, 33, 38, 39). Higher occurrence of the mutation within Collies and other herding breeds has facilitated earlier clinical exploration of precision approaches to analgesia (1, 30–39).
Similarly, the CYP gene family has been linked to drug metabolism across humans and veterinary species. Human CYP2D6 is associated with over 100 alleles, resulting in four metabolic phenotypes for the O-demethylation of codeine into morphine, and further morphine into morphine-6-glucuronide, a metabolite with increased analgesic potency (10). In canines, an identified CYP2D6 orthologue is associated with tramadol variability and is being explored in relation to deracoxib toxicity (45, 59, 60, 62). Further, in equines, two distinct metabolic phenotypes for codeine O-demethylation have been linked to the CYP2D6 orthologue (47–51).
Despite early findings, a substantial knowledge gap persists. Deeper understanding of the underpinning genetic factors in analgesic response is needed to refine therapeutic strategies. To achieve truly effective and humane pain management, veterinary medicine must move beyond traditional standardised frameworks and embrace the development of precision-guided protocols. Nevertheless, without the genetic basis to guide decision making, precision analgesia is inhibited.
3 Barriers to clinical uptake
While precision-guided analgesia holds clear promise, its clinical implementation in veterinary medicine is met with substantial obstacles. Unlike human medicine, where pharmacogenetic integration has benefited from public health funding and pharmaceutical sector support, veterinary pharmacogenetics lacks comparable financial support (1, 5–11, 16, 61). Genetic testing remains prohibitively expensive for many animal owners, and in the absence of insurance coverage or decreased costs, widespread adoption is unlikely without incentivising action (1, 5–11, 16, 61).
Economic constraints extend beyond clinical settings, impacting research momentum. A lack of funding hampers large-scale studies needed to map genotype-phenotype relationships relevant to analgesic response at species- and breed-specific levels. As a result, pharmacogenes remain poorly defined across veterinary species, and many genes of interest lack comprehensive pharmacokinetic and pharmacodynamic data. Additionally, the current evidence is insufficient to convincingly demonstrate improved clinical outcomes (1, 5–11, 14, 16). Consequently, the development of standardised clinical guidelines remains a significant challenge. Without standardised protocols, clinicians may struggle to incorporate genetic insights effectively into therapeutic decisions, exacerbating the lack of research into clinical outcomes (1, 5–11, 16).
Moreover, pharmacogenetic phenotypes are often difficult to identify without pharmacokinetic or pharmacodynamic testing. In the absence of genetic data, clinicians are unable to identify affected individuals, as phenotypic indicators of genetic variants are often not observable. There is poor justification for precision approaches in time-sensitive cases when veterinarians are unable to readily obtain genotype data (1, 61).
Compounding this is the reality that many veterinarians rarely have access to genotype information. Unlike human medicine, where pharmacogenetic data may be embedded into electronic health records, veterinary clinicians often rely on owner curiosity and commercial genomics companies whose services lack regulatory oversight for validation and quality control standards (1, 5–11, 16, 63). Even when genetic data is available, improving genetic literacy among veterinarians must be a parallel priority. Without foundational and continuing education in how to interpret and apply pharmacogenetic data, even the best research and tools will struggle to gain meaningful clinical traction (63, 64). Efforts to centralise genetic information, such as the Online Mendelian Inheritance in Animals, offer academic value but are not currently structured for practical clinical use (16, 63, 65). Without high-quality testing and genetic resources readily available, precision-guided analgesia presently remains difficult to integrate in routine practise (1, 5–11, 16).
These systemic challenges underscore the need for broader infrastructure. Without such foundations, the potential of pharmacogenetics to advance precision medicine in veterinary care will not be fully realised. Only through systemic collaboration can the field move from isolated findings to routine, evidence-based precision pain management.
4 Towards practical integration
Despite these barriers, the future of precision-guided pain management in veterinary medicine is increasingly promising. Several emerging trends in pharmacogenetics point towards its increasingly feasible integration. Advances in genomics, bioinformatics, and clinical pharmacology are converging to create novel opportunities for more effective and individualised analgesic strategies across species.
One of the most exciting prospects for pharmacogenetics lies in the identification of genes that utilise visually apparent phenotypic markers as proxies for underlying genetic variation. Variants in the melanocortin 1 receptor (MC1R) gene, most famously associated with red hair and fair skin in humans, are known to be associated with altered levels of nociceptive regulation (66–68). Particularly in response to opioids, humans and rodents with an MC1R variant typically exhibit increased sensitivity (66–69). In equines, preliminary research has also begun exploring MC1R variants linked to the chestnut coat colour and variability in opioid metabolism (70). The existence of visually recognisable phenotypes tied to quantifiable variability in drug response offers a pragmatic entry point for the integration of pharmacogenetics into clinical practise. If validated, this approach could facilitate the prediction of analgesic needs by bypassing the immediate requirement for genetic testing, allowing more widespread clinical integration of precision pain management.
Where clinically relevant pharmacogenes have been identified, the next step is to ensure that genetic information is accessible at the point of care. The development of genetic arrays for pharmacogenes present in a significant proportion of veterinary species populations may allow for the testing of individuals at birth. This approach could integrate results and clinical interpretation into early health records, ensuring consistent access to genotype-informed guidance throughout the animal's life rather than adapting as sensitivities arise. Greater accessibility to interpretation and results will be able to aid practitioner confidence in pharmacogenetic applications (1–4, 16, 18, 64).
Ultimately, capitalising on these opportunities will require continued investment in species-specific pharmacogenetic research, validation of clinically actionable markers, and development of accessible, cost-effective testing platforms where phenotypes are not easily observable. With coordinated effort, precision-guided pain management could shift from a theoretical possibility to a standard of care, offering substantial improvements in therapeutic efficacy and patient welfare across veterinary medicine.
5 Discussion
Precision medicine offers a transformative opportunity to enhance the efficacy, safety, and individualisation of veterinary treatments. Pain management stands to particularly benefit from the integration of pharmacogenetics, offering a pathway to move beyond the conventional trial-and-error approach that currently defines analgesic therapy. Although early discoveries, such as ABCB1 and CYP2D6, have illustrated the clinical relevance of pharmacogenetics in veterinary species, translation into routine practise remains slow.
Future progress will require interdisciplinary collaboration between clinicians, researchers, and geneticists to develop relevant genetic testing, establish evidence-based guidelines, and incorporate insights into everyday practise. Emerging opportunities, such as the identification of observable phenotypic markers, offer exciting prospects to bridge this gap. Investment in scalable tools, including pharmacogenetic arrays and clinical decision-support systems will be essential to operationalise these advances on a wide scale.
By addressing the current barriers and continuing to invest in foundational and translational research, veterinary precision medicine can shift from theory to practise. The ultimate vision is a veterinary healthcare model where treatments are tailored beyond species- and breed-specific generalisations. Such a transformation would not only optimise therapeutic outcomes but also substantially elevate the standard of care and welfare across all animal populations. Precision-guided veterinary pain management is no longer a distant goal but a realistic clinical objective which demands multidisciplinary collaboration to realise its full potential.
Author contributions
J-LJ: Conceptualization, Writing – original draft, Writing – review & editing, Formal analysis. EB: Conceptualization, Writing – original draft, Writing – review & editing. BV: Conceptualization, Supervision, Writing – original draft, Writing – review & editing.
Funding
The author(s) declare that no financial support was received for the research and/or publication of this article.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Gen AI was used in the creation of this manuscript.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Campion DP, Dowell FJ. Translating pharmacogenetics and pharmacogenomics to the clinic: progress in human and veterinary medicine. Front Vet Sci. (2019) 6:22. doi: 10.3389/fvets.2019.00022
2. Weinshilboum RM, Wang L. Pharmacogenomics: precision medicine and drug response. Mayo Clin Proc. (2017) 92:1711–22. doi: 10.1016/j.mayocp.2017.09.001
3. Nebert DW. Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin Genet. (1999) 56:247–58. doi: 10.1034/j.1399-0004.1999.560401.x
4. Giacomini KM, Yee SW, Ratain MJ, Weinshilboum RM, Kamatani N, Nakamura Y. Pharmacogenomics and patient care: one size does not fit all. Sci Transl Med. (2012) 4:153ps18. doi: 10.1126/scitranslmed.3003471
5. Katogiritis A, Khanna C. Towards the delivery of precision veterinary cancer medicine. Vet Clin North Am Small Anim Pract. (2019) 49:809–18. doi: 10.1016/j.cvsm.2019.04.011
6. Lloyd KC, Khanna C, Hendricks W, Trent J, Kotlikoff M. Precision medicine: an opportunity for a paradigm shift in veterinary medicine. J Am Vet Med Assoc. (2016) 248:45–8. doi: 10.2460/javma.248.1.45
7. Chon E, Hendricks W, White M, Rodrigues L, Haworth D, Post G. Precision medicine in veterinary science. Vet Clin North Am Small Anim Pract. (2024) 54:501–21. doi: 10.1016/j.cvsm.2023.12.006
8. Klopfleisch R. Personalised medicine in veterinary oncology: one to cure just one. Vet J. (2015) 205:128–35. doi: 10.1016/j.tvjl.2015.01.004
9. Buckley RM, Lyons LA. Precision/genomic medicine for domestic cats. Vet Clin North Am Small Anim Pract. (2020) 50:983–90. doi: 10.1016/j.cvsm.2020.05.005
10. Mealey KL, Martinez SE, Villarino NF, Court MH. Personalized medicine: going to the dogs? Hum Genet. (2019) 138:467–81. doi: 10.1007/s00439-019-02020-w
11. Rivas VN, Stern JA, Ueda Y. The role of personalized medicine in companion animal cardiology. Vet Clin North Am Small Anim Pract. (2023) 53:1255–76. doi: 10.1016/j.cvsm.2023.05.016
12. Chan S, Erikainen S. What's in a name? The politics of ‘Precision Medicine'. Am J Bioeth. (2018) 18:50–2. doi: 10.1080/15265161.2018.1431324
13. Erikainen S, Chan S. Contested futures: envisioning “Personalized,” “Stratified,” and “Precision” medicine. New Genet Soc. (2019) 38:308–30. doi: 10.1080/14636778.2019.1637720
14. Swen JJ, Huizinga TW, Gelderblom H, de Vries EG, Assendelft WJ, Kirchheiner J, et al. Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med. (2007) 4:e209. doi: 10.1371/journal.pmed.0040209
15. Roses AD. Pharmacogenetics and the practice of medicine. Nature. (2000) 405:857–65. doi: 10.1038/35015728
16. Vaidhya A, Ghildiyal K, Rajawat D, Nayak SS, Parida S, Panigrahi M. Relevance of pharmacogenetics and pharmacogenomics in veterinary clinical practice: A review. Anim Genet. (2024) 55:3–19. doi: 10.1111/age.13376
17. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. (2005) 23:9312–8. doi: 10.1200/JCO.2005.03.3266
18. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. (2009) 302:1429–36. doi: 10.1001/jama.2009.1420
19. Martinez MN, Court MH, Fink-Gremmels J, Mealey KL. Population variability in animal health: Influence on dose-exposure-response relationships: part I: Drug metabolism and transporter systems. J Vet Pharmacol Ther. (2018) 41:E57–67. doi: 10.1111/jvp.12670
20. Pang LY, Argyle DJ. Veterinary oncology: Biology, big data and precision medicine. Vet J. (2016) 213:38–45. doi: 10.1016/j.tvjl.2016.03.009
21. Kapturska KM, Pawlak A. New molecular targets in canine hemangiosarcoma-Comparative review and future of the precision medicine. Vet Comp Oncol. (2023) 21:357–77. doi: 10.1111/vco.12917
22. Leeb T, Brenig B. Ryanodine receptors and their role in genetic diseases (review). Int J Mol Med. (1998) 2:293–300. doi: 10.3892/ijmm.2.3.293
23. Hall LW, Woolf N, Bradley JW, Jolly DW. Unusual reaction to suxamethonium chloride. Br Med J. (1966) 2:1305. doi: 10.1136/bmj.2.5525.1305
24. Fujii J, Otsu K, Zorzato F, de Leon S, Khanna VK, Weiler JE, et al. Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science. (1991) 253:448–51. doi: 10.1126/science.1862346
25. MacLennan DH, Otsu K, Fujii J, Zorzato F, Phillips MS, O'Brien PJ, et al. The role of the skeletal muscle ryanodine receptor gene in malignant hyperthermia. Symp Soc Exp Biol. (1992) 46:189–201.
26. Roberts MC, Mickelson JR, Patterson EE, Nelson TE, Armstrong PJ, Brunson DB, et al. Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1). Anesthesiology. (2001) 95:716–25. doi: 10.1097/00000542-200109000-00026
27. Aleman M, Riehl J, Aldridge BM, Lecouteur RA, Stott JL, Pessah IN. Association of a mutation in the ryanodine receptor 1 gene with equine malignant hyperthermia. Muscle Nerve. (2004) 30:356–65. doi: 10.1002/mus.20084
28. Aleman M, Brosnan RJ, Williams DC, LeCouteur RA, Imai A, Tharp BR, et al. Malignant hyperthermia in a horse anesthetized with halothane. J Vet Intern Med. (2005) 19:363–6. doi: 10.1111/j.1939-1676.2005.tb02710.x
29. Perez Jimenez TE, Issaka Salia O, Neibergs HL, Zhu Z, Spoor E, Rider C, et al. Novel ryanodine receptor 1 (RYR1) missense gene variants in two pet dogs with fatal malignant hyperthermia identified by next-generation sequencing. Vet Anaesth Analg. (2025) 52:8–18. doi: 10.1016/j.vaa.2024.10.131
30. Mealey KL. Therapeutic implications of the MDR-1 gene. J Vet Pharmacol Ther. (2004) 27:257–64. doi: 10.1111/j.1365-2885.2004.00607.x
31. Mealey KL, Fidel J. P-glycoprotein mediated drug interactions in animals and humans with cancer. J Vet Intern Med. (2015) 29:1–6. doi: 10.1111/jvim.12525
32. Mealey KL. Canine ABCB1 and macrocyclic lactones: heartworm prevention and pharmacogenetics. Vet Parasitol. (2008) 158:215–22. doi: 10.1016/j.vetpar.2008.09.009
33. Mealey KL, Meurs KM. Breed distribution of the ABCB1-1Delta (multidrug sensitivity) polymorphism among dogs undergoing ABCB1 genotyping. J Am Vet Med Assoc. (2008) 233:921–4. doi: 10.2460/javma.233.6.921
34. Mealey KL, Bentjen SA, Gay JM, Cantor GH. Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics. (2001) 11:727–33. doi: 10.1097/00008571-200111000-00012
35. Sartor LL, Bentjen SA, Trepanier L, Mealey KL. Loperamide toxicity in a collie with the MDR1 mutation associated with ivermectin sensitivity. J Vet Intern Med. (2004) 18:117–8. doi: 10.1111/j.1939-1676.2004.tb00145.x
36. Beckers E, Casselman I, Soudant E, Daminet S, Paepe D, Peelman L, et al. The prevalence of the ABCB1-1Delta variant in a clinical veterinary setting: the risk of not genotyping. PLoS One. (2022) 17:e0273706. doi: 10.1371/journal.pone.0273706
37. Myers MJ, Martinez M, Li H, Qiu J, Troutman L, Sharkey M, et al. Influence of ABCB1 genotype in collies on the pharmacokinetics and pharmacodynamics of loperamide in a dose-escalation study. Drug Metab Dispos. (2015) 43:1392–407. doi: 10.1124/dmd.115.063735
38. Henik RA, Kellum HB, Bentjen SA, Mealey KL. Digoxin and mexiletine sensitivity in a Collie with the MDR1 mutation. J Vet Intern Med. (2006) 20:415–7. doi: 10.1111/j.1939-1676.2006.tb02878.x
39. Nelson OL, Carsten E, Bentjen SA, Mealey KL. Ivermectin toxicity in an Australian Shepherd dog with the MDR1 mutation associated with ivermectin sensitivity in Collies. J Vet Intern Med. (2003) 17:354–6. doi: 10.1111/j.1939-1676.2003.tb02461.x
40. Martignoni M, Groothuis GM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol. (2006) 2:875–94. doi: 10.1517/17425255.2.6.875
41. Martinez MN, Antonovic L, Court M, Dacasto M, Fink-Gremmels J, Kukanich B, et al. Challenges in exploring the cytochrome P450 system as a source of variation in canine drug pharmacokinetics. Drug Metab Rev. (2013) 45:218–30. doi: 10.3109/03602532.2013.765445
42. Schneider M, Dron F, Cuinet E, Woehrle F. Comparative pharmacokinetic profile of cimicoxib in dogs and cats after IV administration. Vet J. (2021) 270:105625. doi: 10.1016/j.tvjl.2021.105625
43. Visser M, Zaya MJ, Locuson CW, Boothe DM, Merritt DA. Comparison of predicted intrinsic hepatic clearance of 30 pharmaceuticals in canine and feline liver microsomes. Xenobiotica. (2019) 49:177–86. doi: 10.1080/00498254.2018.1437933
44. Wu Q, Hu Y, Wang C, Wei W, Gui L, Zeng W, et al. Reevaluate In Vitro CYP3A index reactions of benzodiazepines and steroids between humans and dogs. Drug Metab Dispos. (2022) 50:741–9. doi: 10.1124/dmd.122.000864
45. Martinez SE, Shi J, Zhu HJ, Perez Jimenez TE, Zhu Z, Court MH. Absolute quantitation of drug-metabolizing cytochrome P450 enzymes and accessory proteins in dog liver microsomes using label-free standard-free analysis reveals interbreed variability. Drug Metab Dispos. (2019) 47:1314–24. doi: 10.1124/dmd.119.088070
46. Zhao Y, Liang A, Zhang Y, Li C, Yi Y, Nilsen OG. Impact of tetrahydropalmatine on the pharmacokinetics of probe drugs for CYP1A2, 2D6 and 3A isoenzymes in Beagle dogs. Phytother Res. (2016) 30:906–14. doi: 10.1002/ptr.5608
47. Corado CR, McKemie DS, Young A, Knych HK. Evidence for polymorphism in the cytochrome P450 2D50 gene in horses. J Vet Pharmacol Ther. (2016) 39:245–54. doi: 10.1111/jvp.12269
48. Gretler SR, Finno CJ, Kass PH, Knych HK. Functional phenotyping of the CYP2D6 probe drug codeine in the horse. BMC Vet Res. (2021) 17:77. doi: 10.1186/s12917-021-02788-y
49. Knych HK, Baden RW, Gretler SR, McKemie DS. Characterization of the in vitro CYP450 mediated metabolism of the polymorphic CYP2D6 probe drug codeine in horses. Biochem Pharmacol. (2019) 168:184–92. doi: 10.1016/j.bcp.2019.07.005
50. Scantamburlo G, Nofziger C, Paulmichl M, Vanoni S. Genetic analysis of the equine orthologues for human CYP2D6: unraveling the complexity of the CYP2D family in horses. Front Vet Sci. (2023) 10:1188633. doi: 10.3389/fvets.2023.1188633
51. Nakayama SM, Ikenaka Y, Hayami A, Mizukawa H, Darwish WS, Watanabe KP, et al. Characterization of equine cytochrome P450: role of CYP3A in the metabolism of diazepam. J Vet Pharmacol Ther. (2016) 39:478–87. doi: 10.1111/jvp.12303
52. Walters ET, Williams ACC. Evolution of mechanisms and behaviour important for pain. Philos Trans R Soc Lond B Biol Sci. (2019) 374:20190275. doi: 10.1098/rstb.2019.0275
53. Guedes A. Pain Management in Horses. Vet Clin North Am Equine Pract. (2017) 33:181–211. doi: 10.1016/j.cveq.2016.11.006
54. Muir WW. Pain: mechanisms and management in horses. Vet Clin North Am Equine Pract. (2010) 26:467–80. doi: 10.1016/j.cveq.2010.07.008
55. Pedersen TR, Berendt M, Rusbridge C. Neuroanatomy of spinal nociception and pain in dogs and cats: a practical review for the veterinary clinician. Front Vet Sci. (2025) 12:1534685. doi: 10.3389/fvets.2025.1534685
56. Downing R, Della Rocca G. Pain in pets: beyond physiology. Animals. (2023) 13:355. doi: 10.3390/ani13030355
57. Gruen ME, Lascelles BDX, Colleran E, Gottlieb A, Johnson J, Lotsikas P, et al. 2022 AAHA pain management guidelines for dogs and cats. J Am Anim Hosp Assoc. (2022) 58:55–76. doi: 10.5326/JAAHA-MS-7292
58. Bowen IM, Redpath A, Dugdale A, Burford JH, Lloyd D, Watson T, et al. BEVA primary care clinical guidelines: analgesia. Equine Vet J. (2020) 52:13–27. doi: 10.1111/evj.13198
59. Lascelles BD, Blikslager AT, Fox SM, Reece D. Gastrointestinal tract perforation in dogs treated with a selective cyclooxygenase-2 inhibitor: 29 cases (2002-2003). J Am Vet Med Assoc. (2005) 227:1112–7. doi: 10.2460/javma.2005.227.1112
60. McMillan SK, Boria P, Moore GE, Widmer WR, Bonney PL, Knapp DW. Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc. (2011) 239:1084–9. doi: 10.2460/javma.239.8.1084
61. Moses L, Niemi S, Karlsson E. Pet genomics medicine runs wild. Nature. (2018) 559:470–2. doi: 10.1038/d41586-018-05771-0
62. Case JB, Fick JL, Rooney MB. Proximal duodenal perforation in three dogs following deracoxib administration. J Am Anim Hosp Assoc. (2010) 46:255–8. doi: 10.5326/0460255
63. Vlasiou MC. Vet informatics and the future of drug discovery in veterinary medicine. Front Vet Sci. (2024) 11:1494242. doi: 10.3389/fvets.2024.1494242
64. Bogaerts E, den Boer E, Peelman L, Van Nieuwerburgh F, Fieten H, Saunders JH, et al. Veterinarians' competence in applying basic genetic principles and daily implementation of clinical genetics: a study in a university environment. J Vet Med Educ. (2022) 49:799–806. doi: 10.3138/jvme-2020-0029
65. Tammen I, Mather M, Leeb T, Nicholas FW. Online Mendelian Inheritance in Animals (OMIA): a genetic resource for vertebrate animals. Mamm Genome. (2024) 35:556–64. doi: 10.1007/s00335-024-10059-y
66. Ascsillan AA, Kemeny LV. The skin-brain axis: from UV and pigmentation to behaviour modulation. Int J Mol Sci. (2024) 25:6199. doi: 10.3390/ijms25116199
67. Liem EB, Joiner TV, Tsueda K, Sessler DI. Increased sensitivity to thermal pain and reduced subcutaneous lidocaine efficacy in redheads. Anesthesiology. (2005) 102:509–14. doi: 10.1097/00000542-200503000-00006
68. Liem EB, Lin CM, Suleman MI, Doufas AG, Gregg RG, Veauthier JM, et al. Anesthetic requirement is increased in redheads. Anesthesiology. (2004) 101:279–83. doi: 10.1097/00000542-200408000-00006
69. Mogil JS, Ritchie J, Smith SB, Strasburg K, Kaplan L, Wallace MR, et al. Melanocortin-1 receptor gene variants affect pain and mu-opioid analgesia in mice and humans. J Med Genet. (2005) 42:583–7. doi: 10.1136/jmg.2004.027698
Keywords: pharmacogenetics (PGx), analgesia, veterinary genomics, pharmacology, personalised medicine
Citation: Jonovsk J-LC, Bacon EK and Velie BD (2025) Towards precision pain management in veterinary practise: opportunities and barriers. Front. Vet. Sci. 12:1658765. doi: 10.3389/fvets.2025.1658765
Received: 03 July 2025; Accepted: 31 July 2025;
Published: 15 August 2025.
Edited by:
Ismael Hernández Avalos, National Autonomous University of Mexico, MexicoReviewed by:
Claudia Interlandi, University of Messina, ItalyGiovanna Lucrezia Costa, University of Messina, Italy
Elizangela Guedes, Universidade Professor Edson Antônio Velano - UNIFENAS, Brazil
Copyright © 2025 Jonovski, Bacon and Velie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Brandon D. Velie, YnJhbmRvbi52ZWxpZUBzeWRuZXkuZWR1LmF1